Non-Alcoholic Fatty Liver Disease Trial, Recruiting (NCT05842850)

Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT05842850 Sponsor: Steno Diabetes Center Copenhagen Condition: Non-Alcoholic Fatty Liver Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05842850 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Non Alcoholic Fatty Liver Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with non-alcoholic fatty liver disease (NAFLD), meaning their liver has been shown to contain 5% or more fat, confirmed by a specific type of scan called MRS during a related screening study

Who may not be able to join:

People whose BMI (a measure of body weight relative to height) is below 18.5 or above 30
People who have a family history of diabetes in close relatives, including siblings, parents, or grandparents
People who have a condition or take medication known to affect the main outcome being measured in this trial (confirm with trial site)
People who report doing a high level of physical activity
People who drink more alcohol than general health guidelines recommend
People who have a metabolic condition or liver disease (other than NAFLD) (confirm with trial site)
People whose weight has changed by more than 3 kg in the past 6 months, whether gained or lost

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 14 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Charlotte Brøns, PhD, Steno Diabetes Center Copenhagen

Phone: +4526129093

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05842850

Sponsor: Steno Diabetes Center Copenhagen

Phase: Not Applicable

Status: Recruiting

Condition: Non-Alcoholic Fatty Liver Disease

Trial contact: +4526129093

More information: https://clinicaltrials.gov/study/NCT05842850

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with non-alcoholic fatty liver disease (NAFLD), meaning their liver has been shown to contain 5% or more fat, confirmed by a specific type of scan called MRS during a related screening study

Who may not be able to join:

People whose BMI (a measure of body weight relative to height) is below 18.5 or above 30
People who have a family history of diabetes in close relatives, including siblings, parents, or grandparents
People who have a condition or take medication known to affect the main outcome being measured in this trial (confirm with trial site)
People who report doing a high level of physical activity
People who drink more alcohol than general health guidelines recommend
People who have a metabolic condition or liver disease (other than NAFLD) (confirm with trial site)
People whose weight has changed by more than 3 kg in the past 6 months, whether gained or lost

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 14 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Steno Diabetes Center Copenhagen

Registry

ClinicalTrials.gov

Start date

1 January 2026

Est. completion

1 December 2026

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Liver fat content; Liver fat content

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov